Cannabis Science CEO Excited as Record Date for Gifted Shares Approaches Tomorrow, Thursday, March 31st, 2016, and the New 360,000 Sq. Ft., Nevada Facility Moves to Design Phase
(firmenpresse) - COLORADO SPRINGS, CO -- (Marketwired) -- 03/30/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, has announced that the Cannabis Science CEO is excited as record date for gifted shares approaches fast, tomorrow, Thursday, March 31st, 2016, and the new 360,000 sq. ft. facility in Nevada moves into design phase.
The Company will update a secure website platform to include forms for shareholders to report their share ownership and attach any required documentation for transmission directly to Cannabis Science. This will help streamline the process and get shareholders their gifted shares more quickly.
In the same vein as the previously announced 360,000 sq. ft. educational, drug development deal in Nevada has moved into design phase, and the Company has identified other large parcels of land for similar drug development facilities in California. A map of the Nevada facility will be included on the Company website as the Company gets further into the design process and the Company will announce the new land deals in California after signing has been completed.
Cannabis Science has been approached by several investor shareholders and industry professionals looking to expand and capitalize on the Nevada deal. The Company is negotiating with new investors and industry professionals to become a part of the Cannabis Science Research Park, which will help spur new drug research, development, and ultimately manufacturing in addition to scientific contribution and studies.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated bythese forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company''s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ''safe harbor'' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company''s reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
Tel: 813-500-7332
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
Tel: 310.650.3788
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
Tel: 1.888.889.0888
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 1424831
Anzahl Zeichen: 2482
contact information:
Contact person:
Town:
COLORADO SPRINGS, CO
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cannabis Science CEO Excited as Record Date for Gifted Shares Approaches Tomorrow, Thursday, March 31st, 2016, and the New 360,000 Sq. Ft., Nevada Facility Moves to Design Phase
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cannabis Science, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
